PRAEDO AF study
- Conditions
- on-valvular atrial fibrillation
- Registration Number
- JPRN-jRCTs031180119
- Lead Sponsor
- Fukamachi Daisuke
- Brief Summary
The study found clinical acceptance of edoxaban monotherapy in patients with ischemic heart disease with atrial fibrillation 6 months after coronary artery treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 147
Patients with non-valvular atrial fibrillation complicated with stable coronary artery disease who are 20 years or more at the obtaining of informed consent. CHADS2 score are 1 or more, and fulfil the criteria below and can provide written consent for participation in the present study will be eligible.
1) Patients who underwent percutaneous coronary intervention, including plain old balloon angioplasty. At least six months ago
2) Patients who have coronary stenosis requiring no percutaneous coronary intervention (50% or more stenosis) as indicated by coronary CT or coronary angiography
3) Patients who underwent coronary artery bypass graft CABG at least six months ago
1) Patients who are contraindicated for Edoxaban
2) Patients who are contraindicated for Clopidgrel
3) Patients who are going to undergo revascularization
4) Those who are going undergo invasive surgery (excluding digestive endoscopy and biopsy
5) Patients who have active tumors
6) Patients who have poorly-controlled hypertension (systolic blood
pressure at hospital admission:160mmHg or more)
7) Patients judged as inappropriate for this study by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method